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Allogeneic hematopoietic stem cell transplantation (HSCT) with reduced-intensity conditioning (RIC) offers a
potential cure for patients with myelodysplastic syndrome (MDS) who are ineligible for standard-intensity
regimens. Previously published data from our institution suggest excellent outcomes at 1 yr using a uni-
form fludarabine, busulfan, and alemtuzumab-based regimen. Here we report long-term follow-up of 192
patients with MDS and acute myelogenous leukemia (AML) secondary to MDS (MDS-AML) transplanted with
this protocol, using sibling (n ¼ 45) or matched unrelated (n ¼ 147) donors. The median age of the cohort was
57 yr (range, 21 to 72 yr), and median follow-up was 4.5 yr (range, 0.1 to 10.6 yr). The 5-yr overall survival
(OS), event-free survival, and nonrelapse mortality were 44%, 33%, and 26% respectively. The incidence of de
novo chronic graft-versus-host disease (GVHD) was low at 19%, illustrating the efficacy of alemtuzumab for
GVHD prophylaxis. Conversely, the 5-yr relapse rate was 51%. For younger patients (age <50 yr), the 5-yr OS
and relapse rates were 58% and 39%, respectively. On multivariate analysis, advanced age predicted signifi-
cantly worse outcomes, with patients age >60 yr having a 5-yr OS of 15% and relapse rate of 66%. Patients
receiving preemptive donor lymphocyte infusions had an impressive 5-yr OS of 67%, suggesting that this
protocol may lend itself to the incorporation of immunotherapeutic strategies. Overall, these data demon-
strate good 5-yr OS for patients with MDS and MDS-AML undergoing alemtuzumab-based RIC-HSCT. The low
rate of chronic GVHD is encouraging, and comparative studies with other RIC protocols are warranted.
Crown Copyright  2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow
Transplantation. All rights reserved.INTRODUCTION Even though the first report of HSCT for MDS was pub-
Allogeneic hematopoietic stem cell transplantation
(HSCT) remains the only curative therapy for patients with
myelodysplastic syndrome (MDS) and acute myelogenous
leukemia (AML) secondary to MDS (MDS-AML). The devel-
opment of reduced-intensity conditioning (RIC) regimens
has extended this treatment modality to older patients and
those with comorbidities. Post-transplantation survival es-
timates range from 20% to 60%, with variation related toMDS
subtype, disease risk, cytogenetics, and conditioning in-
tensity [1-4]. Despite major advances in supportive care and
decreases in nonrelapse mortality (NRM), relapse and graft-
versus-host disease (GVHD) remain major limitations to the
long-term success of this procedure. High rates of chronic
GVHD (cGVHD), on the order of 40% to 52%, have been re-
ported [5,6], a problem compounded by the need for
continuing immunosuppression and complications related
to prolonged corticosteroid administration.dgments on page 116.
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13.10.021lished many years ago, data on long-term outcomes of
RIC-HSCT for MDS remain limited. Registry studies contain
heterogeneous populations and varied conditioning pro-
tocols. The use of T cell depletion (TCD) as part of the RIC
protocol has the potential to decrease rates of GVHD, thus
further improving NRM and quality of life. Concerns associ-
ated with this approach include a decreased graft-versus-
leukemia effect, particularly with RIC protocols [6], and
increased rates of infection, particularly of viral infections,
such as cytomegalovirus (CMV). Pharmacologic TCD is
generally achieved with either antithymocyte globulin or
alemtuzumab, a monoclonal antibody directed against CD52.
Early data from our institution demonstrate excellent out-
comes at 1 yr with fludarabine and busulfan combined with
alemtuzumab (FBC) in sibling and unrelated donor allografts
[7]. Here we present the largest single-institution analysis
to date of long-term outcomes of 192 patients who under-
went RIC-HSCT for MDS or MDS-AML using a uniform
alemtuzumab-based RIC protocol.MATERIALS AND METHODS
Medical records of all patients with MDS or MDS-AML receiving an FBC-
based protocol between 1999 and 2009 were identified. MDS-AML was
diagnosed based on the presence of previous MDS or morphologicalInc. on behalf of American Society for Blood and Marrow Transplantation.
Table 1
Patient Demographic Data
Characteristic Value
No. of patients 192
Age, yr, median (range) 57 (21-72)
Age group, n (%)
<50 yr 55 (29)
50-60 yr 72 (37)
>60 yr 65 (34)
Diagnosis, n (%)
RCMD/RARS 48 (25)
RAEB 46 (24)
MDS-AML 86 (45)
CMML 12 (6)
IPSS category, n (%)
Low 8 (4)
Int-1 42 (22)
Int-2 35 (18)
High 9 (5)
AML 86 (45)
Cytogenetics, n (%)
Good 63 (33)
Intermediate 92 (48)
Poor 32 (17)
Donor type, n (%)
Sibling 44 (23)
MUD 148 (77)
HLA match, n (%)
Matched 151 (79)
1 antigen mismatched 41 (21)
Stem cell source, n (%)
BM 51 (26)
PBSCs 141 (74)
HCT-CI, n (%)
0 48 (25)
1 40 (21)
2 100 (52)
Status at transplantation, n (%)
No chemotherapy 37 (19)
CR1 122 (64)
CR2 24 (13)
>5% blasts 9 (5)
V.T. Potter et al. / Biol Blood Marrow Transplant 20 (2014) 111e117112dysplasia at the time of AML diagnosis. All diagnostic specimens were
reviewed by specialist hematopathologists. Cytogenetic categories were
allocated according to the International Prognostic Scoring System (IPSS) for
MDS and European Leukaemia Net recommendations for patients with
MDS-AML. In view of the recent publication of a revised cytogenetic clas-
sification system for MDS [8], patients were also categorized according to
this system to evaluate their potential for additional stratification in the
setting of RIC-HSCT.
The FBC RIC protocol includes 30 mg/m2 fludarabine i.v. (on days 9
to 5); 4 mg/kg busulfan orally or 3.2 mg/kg i.v. (on days 3 to 2), and
20 mg alemtuzumab i.v. (on days 8 to 4). All patients with an excess of
blasts were treated with the aim of achieving <5% blasts before HSCT. Do-
nors were fully HLA-matched siblings, matched unrelated donors (MUDs),
or 1-antigen-mismatched unrelated donors. Hematopoietic stem cells from
either peripheral blood stem cells (PBSCs) or bone marrow (BM) were
infused on day 0. Immunosuppression was achieved with 1.5 mg/kg cyclo-
sporin i.v. twice daily starting on day1, with the dose titrated tomaintain a
plasma trough level of 150 to 200 ng/L. The i.v. cyclosporin was changed to
the oral form when clinically appropriate and tapered from day þ56 in the
absence of GVHD, with the aim of stopping cyclosporin by day þ100.
All patients received standard anti-infective prophylaxis in accordance
with institutional guidelines. Recipients were screened weekly for CMV
reactivation as described previously [7] for the first 6 mo, then every
2weeks until immunosuppressionwas completelywithdrawn and no GVHD
was present.
Chimerismwas assessed by XY fluorescence in situ hybridizationwhen a
donorerecipient sex mismatch existed and/or by PCR and fluorescent
analysis of short tandem repeat sequences on BM, whole blood, and pe-
ripheral blood CD3 and CD15 cell fractions. Chimerism assessment was
scheduled for days þ28, þ56, þ100, and þ180 and then every 6 months
thereafter. Preemptive donor lymphocyte infusion (pDLI) was administered
in the presence of evidence of recipient chimerism (donor CD3 <95%)
despite withdrawal of immunosuppression or decreasing donor CD3 by
>20% over 1 mo. DLI was also administered therapeutically (tDLI) as part of
treatment for relapsed disease.
Response was assessed morphologically and, when a previous karyo-
typic abnormality was present, by conventional cytogenetics. Diagnosis
of relapse in patients with a primary diagnosis of refractory anemia (RA)
or refractory cytopenia with multilineage dysplasia (RCMD) required evi-
dence of dysplasia by BM morphology in combination with cytopenias or
reemergence of a previous cytogenetic abnormality. Increasing recipient
chimerism provided supportive evidence of relapse in this context.
GVHDwas assessed based on guidelines of the Consensus Conference on
GVHD Grading and confirmed histologically when possible. CGVHD was
classified according to consensus criteria [9]. De novo GVHD was defined as
onset of GVHD before DLI administration. Graft failure was defined as a
neutrophil count <0.5  109/L beyond day þ28 and/or evidence of loss of
donor cells on the basis of cytogenetics or chimerism studies in the absence
of relapse. Overall survival (OS) was measured from day 0 to death from any
cause; event-free survival (EFS), from day 0 to the first indicator of relapse,
graft failure, or death; and nonrelapse mortality (NRM), from day 0 to death
without evidence of relapse.
Statistical analyses were performed using SPSS version 20 (IBM,
Armonk, NY). Survival curves for the entire cohort were generated by the
Kaplan-Meier method. The log-rank test was used to assess the effect of
variables including age, sex, disease group (World Health Organization
category), IPSS, Hematopoietic Stem Cell Transplantation Comorbidity Index
(HCT-CI) (0 versus 1 versus 2), cytogenetic risk, disease status at time of
transplantation (complete remission versus >5% blasts), donor type (sibling
versus MUD), HLA disparity, and source of stem cells (PBSCs versus BM) on
OS, EFS, relapse, and NRM. Variables included in multivariate analysis were
those displaying significant association with a transplantation outcome in
univariate analysis. The Cox proportional hazards model was used for
multivariate analysis; independent variables with P ¼ .10 were sequentially
excluded from the model. The P value was set at .05 for statistical signifi-
cance. A competing-risk analysis was performed to assess the effect of
cGVHD on relapse.
RESULTS
A total of 192 consecutive patients (86 females, 106
males) with MDS and MDS-AML receiving FBC RIC-HSCT
were identified. Patient characteristics are detailed in
Table 1. Median follow-up was 4.5 yr (range, 0.1 to 10.6 yr),
and median age of the cohort was 57 yr (range, 21 to 72 yr).
Diagnoses included RA, RCMD, refractory anemiawith excess
of blasts (RAEB), chronic myelomonocytic leukemia (CMML),
andMDS-AML. All 86 patients with MDS-AML received high-dose combination chemotherapy before transplantation. Of
46 patients with RAEB, 40 patients received combination
chemotherapy, 4 received 5-azacitidine and 2 received no
treatment. Of 12 patients with CMML, 11 received combina-
tion chemotherapy and 1 received no treatment. Nine of the
48 patients with RCMD received a single course of combi-
nation chemotherapy, 11 patients had received previous
immunosuppressive therapy, 9 patients had failed erythro-
poietin. and 19 patients received no treatment.
OS and EFS
Data for 1- and 5-yr OS, EFS, and relapse are summarized
in Tables 2 and 3. For the entire cohort, 5-yr OS was 44% and
5-yr EFS was 33% (Figure 1A and B). Univariate analysis
identified no significant difference for OS or EFS for donor
type (sibling versus MUD), HLA match (10/10 versus 9/10),
and cytogenetic category (good versus intermediate versus
poor). Patients with an HCT-CI of 0 had better OS and EFS
than patients with an HCT-CI of 2 (OS, 59% versus 33%
versus 40%; P ¼ .06; EFS, 48% versus 31% versus 24%;
P ¼ .008). Greater than 5% blasts at time of transplantation
was significantly associated with poorer OS and EFS
(P < .001). There was a trend toward poorer OS for patients
with higher IPSS scores and significantly worse 5-yr OS and
EFS for patients with RAEB (OS, 24%, P ¼ .008; EFS, 9%,
P ¼ .001) and CMML (OS, 25%, P ¼ .006; EFS, 25%, P ¼ .08)
versus RA/RCMD (OS, 57%; EFS, 48%). For EFS, patients
Table 3
NRM and Relapse Rate
NRM P Value Relapse P Value
1-yr 5-yr 1-yr 5-yr
Age, yr
<50 15 18 30 39
50-60 14 20 NS 23 46 NS
>60 33 48 .01 48 66 .004
Diagnosis
RCMD/RA 18 24 20 31
RAEB 22 38 NS 47 77 .001
AML 19 24 NS 31 56 NS
CMML 28 28 NS 64 64 .03
IPSS
Low 25 25 NS 0 0 .07
Int-1 21 28 21 45
Int-2 19 25 NS 44 66 .08
High 11 100 NS 61 81 .04
AML 19 24 NS 31 56 NS
Cytogenetics
Good 17 22 23 43
Intermediate 22 29 NS 38 50 NS
Poor 21 29 NS 42 56 NS
Donor type
Sibling 16 30 41 51
MUD 21 24 NS 31 50 NS
HLA match
Matched 17 25 36 50
1 antigen mismatched 30 30 NS 33 48 NS
Stem cell source
PBSCs 21 30 33 50
BM 17 17 NS 31 50 NS
HCT-CI
0 12 21 21 31
1 21 36 NS 35 45 NS
2 15 15 NS 40 64 .03
Status at transplantation*
No chemotherapy 17 24 4 14
CR1 21 30 NS 35 54 .001
CR2 21 21 NS 50 65 <.001
Remission status
<5% blasts 21 27 31 48
>5% blasts 0 0 NS 87 100 <.001
* Patients who received no chemotherapy had low-risk MDS (RCMD/RA)
and <5% blasts.
Table 2
OS and EFS
OS, %
(95% CI)
P Value EFS, %
(95% CI)
P Value
1-yr 5-yr 1-yr 5-yr
Age, yr
<50 72 58 55 44
50-60 70 56 NS 60 38 NS
>60 43 15 <.001 33 14 <.001
Diagnosis
RCMD/RA 71 63 58 45
RAEB 59 24 .008 37 9 .001
AML 61 46 NS 55 39 NS
CMML 33 25 .006 25 25 .08
IPSS
Low 75 75 75 75
Int-1 66 52 NS 50 31 .07
Int-2 65 38 NS 40 17 .01
High 56 0 .06 33 0 .01
AML 61 46 NS 55 39 NS
Cytogenetics
Good 72 53 57 36
Intermediate 57 42 NS 45 31 NS
Poor 53 35 NS 47 31 NS
Donor type
Sibling 70 44 50 30
MUD 59 44 NS 50 32 NS
HLA match
Matched 63 45 50 32
1 antigen mismatched 53 40 NS 46 32 NS
Stem cell source
PBSCs 62 42 49 31
BM 59 48 NS 55 38 NS
HCT-CI
0 73 59 63 48
1 55 33 .03 52 31 NS
2 56 40 .04 41 24 .008
Status at transplantation*
No chemotherapy 80 70 70 54
CR1 58 40 NSy 47 28 NSy
CR2 62 42 42 29
Remission status
<5% blasts 63 46 51 33
>5% blasts 30 0 <.001 11 0 <.001
NS indicates not significant.
* Patients who received no chemotherapy had low-risk MDS (RCMD/RA)
and <5% blasts.
y For CR1 versus CR2.
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outcomes comparedwith those classified as low risk (P¼ .01).
With regard to OS and EFS, younger patients had improved
outcomes comparedwith patients age>60 yr; (Figure 2) 5-yr
OS was 56% for patients age 50 to 60 yr, 58% for those age
<50 yr, and 15% for those age >60 yr at the time of trans-
plantation (P < .001). On multivariate analysis, age and >5%
blasts at the time of transplantation retained significance for
bothOS andEFS (forOS: relative risk [RR], 2.5; 95% confidence
interval [CI], 1.6 to 3.8 for age>60 yr and RR. 2.9; 95% CI,1.2 to
7.3 for blasts >5%; for EFS: RR, 1.9; 95% CI, 1.3 to 2.8 for age
>60 yr and RR, 3.5; 95% CI, 1.5 to 8.2 for >5% blasts).
A landmark analysis performed on patients alive at 1 yr
(n ¼ 108) demonstrated 5-yr OS and EFS of 72% and 54%,
respectively. When this group was analyzed separately, age
was the sole factor retaining significance for OS with 5-yr OS
of 36% for patients age >60 yr compared with 80% for pa-
tients age <60 yr at the time of transplantation: RR, 4.0 (95%
CI, 1.8 to 9.1) for age >60 yr. For EFS, both age and HCT-CI
were significant on multivariate analysis: RR, 2.5 (95% CI,
1.3 to 5.0) for age >60 yr and RR, 1.3 (95% CI, 1.0 to 1.7) for
HCT-CI >0.Relapse
The 5-yr relapse rate for the entire cohort was 51%
(Figure 1C). No significant effect was found for donor type,
stem cell source, degree of HLA match, or cytogenetics,
whereas e patients with high IPSS score, diagnosis of RAEB or
CMML versus RA/RCMD, age >60 yr, HCT-CI 2, and >5%
blasts at the time of transplantation had worse outcomes in
terms of relapse (Table 3). On multivariate analysis, age, >5%
blasts and HCT-CI retained significance (RR, 1.9 [95% CI, 1.2 to
3.2] for age>60 yr; RR, 6.4 [95% CI, 2.7 to 15] for>5% blasts at
time of transplantation; and RR, 1.3 [95% CI, 1.0 to 1.6] for
HCT-CI >0).
Patients who relapsed before 100 d, before 365 d, and
after 1 yr were analyzed in an attempt to identify predictors
of early relapse. Of 19 patients who relapsed before day 100,
12 (63.2%) were age>60 yr, comparedwith 6 patients (31.6%)
age 50 to 60 yr and only 1 patient (5.3%) age<50 yr (P ¼ .01).
No difference was found for diagnosis (RA/RCMD versus
RAEB versus AML versus CMML), cytogenetics, IPSS, remis-
sion status (compete remission [CR] 1 versus CR2), or >5%
blasts pretransplantation. Although these values were not
statistically significant, likely owing to small numbers on
stratification, of note, 5 of 9 patients with >5% blasts at the
time of transplantation (56%) had relapsed before day 100
and 8 (89%) had relapsed before 1 yr.
Figure 1. (A) 5-yr OS for 192 patients receiving FBC RIC-HSCT. (B) 5-yr EFS for 192 patients receiving FBC RIC-HSCT. (C) 5-yr relapse rate for 192 patients receiving FBC
RIC-HSCT. (D) 5-yr NRM for 192 patients receiving FBC RIC-HSCT.
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An additional analysis performed to evaluate the effect of
the revised cytogenetic criteria in patients undergoing HSCT
with a diagnosis of MDS (n¼ 94) revealed significantly worse
outcomes (P < .001) in terms of both OS and EFS in patients
with very-poor-risk cytogenetics (n ¼ 6) compared with
those in all other categories. No patients in this cohort were
classified in the very-good-risk cytogenetic group. Median
OS and EFS post-HSCT for the very-poor-risk group was low,
155 d (range, 50 to 363 d) and 83 d (range, 50 to 242 d),
respectively.
Relapse rates were significantly worse for the patients
with very-poor-risk cytogenetics compared with those with
good-risk (n ¼ 55) and intermediate-risk (n ¼ 23) patients,
but not compared with poor-risk patients (n ¼ 10). All very-
poor-risk patients had relapsed within 8 mo (the earliest at
day þ83), and 78% of poor-risk patients had relapsed by
25 mo (earliest at day þ63 d). Patients with very-poor-risk
cytogenetics also had worse NRM, with a day þ100 NRM of
34%, compared with 10% for poor-risk (P ¼ .06), 0% for
intermediate-risk (P ¼ .01), and 2% for good-risk (P ¼ .008)
patients.
Engraftment and Chimerism
The majority of patients (n ¼ 141) received PBSCs at
median dose of 6.40  106/kg (range, 1.09 to 17.5  106/kg).
Fifty-one patients received BM at a median dose of
2.59  106/kg (range, 0.44 to 13.7  106/kg). Neutrophil and
platelet engraftment occurred at a median of 13 d and 15 d,
respectively. Graft failure occurred in only 14 patients (7%;
primary in 7 and secondary in 7). Eight of those 14 patients
underwent a second transplantation, 3 of whom were alive
at the time of this report. Five patients died of complicationssecondary to graft failure, and 1 patient was alive with
autologous reconstitution.
Data on CD3 chimerismwere available for 103 patients at
day þ28, 117 patients at day þ100, 90 patients at day þ180,
and 82 patients at 1 yr. Rates of mixed T cell chimerismwere
at 63.1% at day þ28, 63.2% at day þ56, 57.3% at day þ100
52.2% at day þ180, and 47.6% at 1 yr.
NRM and Causes of Death
Data for NRM are summarized in Table 3. NRM was 5% at
100 d and 20% at 1 yr. Overall NRM at 5 yr remained low at
26% (Figure 1D). Donor type, degree of HLA matching, HCT-
CI, IPSS, cytogenetics, and World Health Organization cate-
gory had no significant association with NRM. Advanced age
was associated with higher rates of NRM, with a 1-yr NRM of
33% and a 5-yr NRM of 48% in patients age >60 yr, compared
with 14% and 20% in patients age 50 to 60 yr and 15% and 18%
in patients age <50 yr (P ¼ .01).
At the time of censoring, 101 patients had died. Cause of
death included relapse in 52, GVHD in 10, sepsis in 9, mul-
tiorgan failure in 5, fungal infection in 2, graft failure in 6,
cerebral hemorrhage in 2, veno-occlusive disease in 2, post-
transplantation lymphoproliferative disorder (PTLD) in 2,
CMV pneumonitis in 1, disseminated adenovirus and CMV
hepatitis in 1, pulmonary embolism in 1, and definitive cause
unidentifiable in 8.
Acute and Chronic GVHD
Acute GVHD (aGVHD) was diagnosed in 66 patients (34%),
39 with grade III-IV aGVHD (20%). De novo cGVHD occurred
in only 37 patients (19%). According to National Institutes of
Health criteria, the global grade of cGVHD was moderate in
13 patients (6.5%) and severe in 7 (3.5%). Five patients (2.5%)
Figure 2. (A) Effect of age on 5-yr OS. (B) Effect of age on 5-yr EFS.
V.T. Potter et al. / Biol Blood Marrow Transplant 20 (2014) 111e117 115were classified as having overlap syndrome of GVHD. Death
was attributed to GVHD in only 2 of the 13 patients with
moderate GVHD, compared with 2 of the 7 patients with
severe cGVHD. All patients with overlap syndrome subse-
quently died, 2 from relapse, 1 from sepsis, 1 with multiple
cerebral lesions (definitive cause not identified), and 1 from
GVHD (skin/gut). A competing-risk analysis performed to
assess the effect of de novo cGVHD on relapse (with death as
competing risk) demonstrated no association of cGVHD with
decreased relapse.DLI
DLI was administered to 73 patients (38%). Themajority of
these patients (n ¼ 44; 60%) received pDLI for falling or
inadequate CD3 chimerism, whereas the remainder (n ¼ 29;
40%) received tDLI as treatment for relapsed disease. In the
patients who received pDLI, the median CD3 before DLI was
20% (range, 0 to 59%), and the median time to DLI was 169 d
(range, 87 to 1297 d). Patients received a median of 2 courses
(range, 1 to 5), with a median dose of 5.5  106 CD3 cells/kg
(range, 5  105 to 1.66  108 CD3 cells/kg). In the patients
who received tDLI, the median CD3 before DLI was 87%
(range, 7% to 100%), and the median time to DLI was 256 d
(range, 74 to 1304 d). Patients received a median of 2 courses
(range 1 to 8) with a median dose of 6.5  106 CD3 cells/kg
(range, 5  105 to 1.43  108 CD3 cells/kg). Of the patients
receiving pDLI, 30 (68%) attained full donor chimerism (FDC),
4 (8%) attained stable mixed chimerism, and 10 (23%) had no
response. Of the patients who received tDLI, 6 (21%) achieved
long-term remission, 4 (14%) attained CR and then subse-
quently relapsed, and 19 (65%) did not respond. Thirty-three
patients (46%) developed GVHD post-DLI. The patients who
received pDLI had a 5-yr OS of 67%, compared with 37% in
those receiving tDLI. Ten patients age >60 yr received pDLI;
these patients had a 5-yr OS of 67%, similar to that in patients
age <60 yr.Figure 3. 5-yr OS according to disease category.CMV and PTLD
A total of 119 patients were considered at risk for CMV
reactivation on the basis of donor or recipient serology. Of
these, 75 patients (63%) developed CMV reactivation. Only 8
patients (4%) had CMV disease (2 with hepatitis, 4 with
pneumonitis, and 2 with colitis). Overall, there were 3
documented cases of biopsy-proven PTLD, of whom 2 died
and 1 was successfully treated with rituximab.DISCUSSION
To our knowledge, this study comprises the largest cohort
of patients with MDS and MDS-AML treated with uniform
alemtuzumab-based RIC-HSCT reported to date. We found
favorable long-term outcomes with high OS and, impor-
tantly, low NRM and rate of GVHD in patients age <60 yr. In
other alemtuzumab-based protocols, long-term survival es-
timates have ranged from 31% at 3 yr to 45% at 4 yr [10-12]. A
recent large Center for International Blood and Marrow
Transplant Research (CIBMTR) analysis reported 5-yr OS of
33% for RIC protocols (mainly T cell replete) and a European
Group for Blood and Marrow Transplantation analysis re-
ported a 4-yr OS of 31% in patients age >50 yr [13]. Our re-
ported 5-yr OS of 44% for our entire cohort compares
favorably with the results of those studies. In addition, our
landmark analysis of patients alive at 1 yr, indicating excel-
lent long-term survival, suggests low rates of later compli-
cations with this protocol.
Of note, high rates of OS and EFS (46% and 39%, respec-
tively) were observed for our patients with MDS-AML
(Figure 3), a group traditionally associated with poorer
prognoses. Young patients with MDS-AML had a 5-yr OS of
65% and 5-yr EFS of 55%. Younger patients and those with
low-risk disease did particularly well on this protocol, with a
5-yr OS of 74% and 5-yr EFS of 55% in patients age<50 yr and
thosewith RCMD/RA. This finding compares well with the OS
reported in other low-risk cohorts [14] and suggests that
V.T. Potter et al. / Biol Blood Marrow Transplant 20 (2014) 111e117116transplantation for lower-risk disease is a viable option,
resulting in sustained long-term remissions.
Of particular significance in this study are the low rates of
aGVHD and cGVHD, indicating that long-term survival is
achievable without the potentially debilitating effects of
cGVHD. Only 20 patients (10%) had moderate or severe de
novo cGVHD, and only 10 patients (9.9%) had death attrib-
utable to any form of GVHD (acute, chronic, or post-DLI),
despite the fact that the majority of patients (77%) received
stem cells from an unrelated donor. This protocol is also
associated with a low NRM of only 5% at 100 d and 20% at
1 yr. Of note, NRM did not continue to increase significantly
in the subsequent years, with a 5-yr NRM of 26% for the
entire cohort. This finding likely reflects the low rate of
cGVHD, and suggests that TCD does not lead to longer-term
infection-related mortality. This suggestion is supported by
the low number of patients with death attributed to infec-
tion, 12% (13 of 101) at the time of censoring.
A major concern with the use of TCD is an increased rate
of viral infection, particularly CMV [15]. In our analysis,
although 63% of the patients at risk developed CMV reac-
tivation, the rate of clinically important CMV disease was
extremely low, occurring in only 4% and contributing to
death in only 2 patients (<1%). Furthermore, PTLD was
diagnosed in only 3 patients.
Although the rates of GVHD are low in the FBC protocol,
the relapse rates are of concern. The majority of relapses
occurred in the first year post-transplantation, particularly in
patients with high-risk disease features, such as high IPSS
score, RAEB versus RCMD, older age, and poor-risk cytoge-
netics (Table 3). Despite the observed 5-yr relapse rate of
51%, OS remained good for this cohort, suggesting that
although relapse occurs, a number of patients can be
salvaged. This is illustrated by the 5-yr OS of 37% in patients
receiving DLI for relapse, a figure considerably better than
reported for most patients who relapse post-transplantation
[16]. Indeed, patients who received pDLI to revert low or
falling donor chimerism demonstrated a very good 5-yr OS of
67%, suggesting that this protocol may lend itself to the
incorporation of immune therapies, such as DLI, that can
promote long-term OS post-transplantation. A more detailed
analysis of the use of DLI in the TCD setting by our group
supports this theory [17], demonstrating excellent long-term
outcomes in patients with MDS or AML after pDLI. In view of
these findings, current recommendations in our institution
are to administer pDLI as the standard of care for patients
with low or falling chimerism, with a prospective clinical
trial planned to further substantiate these findings.
Our results confirm those from previous studies [18,19]
indicating that remission status at the time of trans-
plantation is important for OS and EFS. Although only 9 of
our patients had >5% blasts at the time of transplantation,
none of these patients was alive and free of disease at 5 yr,
and all but 1 had relapsed within 1 yr. For these patients,
whether results may be improved by increasing the busulfan
component of this protocol or by altering TCD is unclear.
Although we failed to demonstrate a significant impact of
IPSS cytogenetics on outcomes, reclassification of the group
according to revised cytogenetic criteria demonstrated
poorer outcomes and short median survival for those with
very-poor-risk cytogenetics. Although this group of patients
was small, this finding emphasizes the importance of
applying refinements in disease stratification to patient se-
lection for transplantation, allowing more accurate predic-
tion of post-transplantation outcomes. Future studiesincorporating this knowledge will be important with respect
to developing novel therapies or intensifying post-
transplantation strategies aimed at relapse prevention.
Outcomes in patients age >60 yr were inferior, with
higher rates of relapse and NRM contributing to lower OS
and EFS. Reasons for this were not definitively identifiable;
these patients did not have significant differences in terms of
adverse prognostic factors, such as poor-risk cytogenetics or
greater proportion of higher HCT-CI scores, compared with
the remainder of the group. Advanced age retained the
greatest significance onmultivariate analysis for both OS and
EFS; thus, it is possible that unmeasured factors relating to
disease biology or immune reconstitution are important in
the elderly. Of note, the majority of the 19 patients who
relapsed before 100 d post-HSCT were age >60 yr.
Poorer outcomes in patients age >60 yr receiving alem-
tuzumab in combination with melphalan have been reported
previously [20]; however, our data relating to age conflict
with findings from a recent large CIBMTR analysis of non-
myeloablative and RIC HSCT [21]. Most patients in the
CIBMTR analysis did not receive TCD, possibly contributing
to the different outcomes. It is conceivable that the effect of
TCD might be more pronounced in the elderly population,
in whom immune reconstitution is already compromised
[22-24]. Strategies to address this effect include decreasing
the alemtuzumab dose, an approach shown to be feasible in
other studies [25,26], or using pDLI, which we found to result
in sustained remissions as outlined above. Interestingly, in the
data presented herein, although the number of patients age
>60 yr who received pDLI was small, the 5-yr OS was high
at 67%.
In summary, this analysis demonstrates very good long-
term outcomes for patients age <60 yr receiving FBC
RIC-HSCT, with low rates of NRM and GVHD despite the
predominantly unrelated donor setting. Although relapse is
an issue, this protocol provides an ideal basis for RIC-HSCT,
and can act as a platform for subsequent immune therapies
such as DLI, resulting in sustained remissions. Future di-
rections could involve prospective trials assessing the value
of busulfan dose intensification, early pDLI, or use of
adjunctive post-transplantation pharmacotherapeutic stra-
tegies to minimize relapse.ACKNOWLEDGMENTS
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